Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

被引：0
作者：
Robert M Eager
C Casey Cunningham
Neil N Senzer
Joe Stephenson
Stephen P Anthony
Steven J O'Day
Gary Frenette
Anna C Pavlick
Barry Jones
Margaret Uprichard
John Nemunaitis
机构：
[1] Mary Crowley Cancer Research Centers,Clinical Research Unit
[2] Texas Oncology PA,Department of Dermatology
[3] Baylor Sammons Cancer Center,Department of Internal Medicine
[4] Gradalis,undefined
[5] Inc,undefined
[6] Cancer Centers of the Carolinas,undefined
[7] Cancer Care Northwest,undefined
[8] The Angeles Clinic and Research Institute,undefined
[9] Carolinas Medical Center,undefined
[10] New York University Clinical Cancer Center,undefined
[11] Point Therapeutics,undefined
[12] Inc,undefined
[13] The University of Hawaii,undefined
来源：
BMC Cancer | / 9卷
关键词：
Metastatic Melanoma; Evaluable Patient; Dipeptidyl Peptidase; Fibroblast Activation Protein; Index Lesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study
    van der Hiel, Bernies
    Haanen, John B. A. G.
    Stokkel, Marcel P. M.
    Peeper, Daniel S.
    Jimenez, Connie R.
    Beijnen, Jos H.
    van de Wiel, Bart A.
    Boellaard, Ronald
    van den Eertwegh, Alfons J. M.
    BMC CANCER, 2017, 17
  • [42] Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial
    Hofmann, Maja A.
    Hauschild, Axel
    Mohr, Peter
    Garbe, Claus
    Weichenthal, Michael
    Trefzer, Uwe
    Drecoll, Ulrike
    Tilgen, Wolfgang
    Schadendorf, Dirk
    Kaatz, Martin
    Ulrich, Jens
    MELANOMA RESEARCH, 2011, 21 (06) : 516 - 523
  • [43] A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma
    Kudchadkar, Ragini
    Ernst, Scott
    Chmielowski, Bartosz
    Redman, Bruce G.
    Steinberg, Joyce
    Keating, Anne
    Jie, Fei
    Chen, Caroline
    Gonzalez, Rene
    Weber, Jeffrey
    CANCER MEDICINE, 2015, 4 (05): : 643 - 650
  • [44] A Phase 2 Trial of Complete Resection for Stage IV Melanoma Results of Southwest Oncology Group Clinical Trial S9430
    Sosman, Jeffrey A.
    Moon, James
    Tuthill, Ralph J.
    Warneke, James A.
    Vetto, John T.
    Redman, Bruce G.
    Liu, P. Y.
    Unger, Joseph M.
    Flaherty, Lawrence E.
    Sondak, Vernon K.
    CANCER, 2011, 117 (20) : 4740 - 4746
  • [45] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
    Weber, Jeffrey
    Thompson, John A.
    Hamid, Omid
    Minor, David
    Amin, Asim
    Ron, Ilan
    Ridolfi, Ruggero
    Assi, Hazem
    Maraveyas, Anthony
    Berman, David
    Siegel, Jonathan
    O'Day, Steven J.
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5591 - 5598
  • [46] First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
    von Moos, R.
    Seifert, B.
    Simcock, M.
    Goldinger, S. M.
    Gillessen, S.
    Ochsenbein, A.
    Michielin, O.
    Cathomas, R.
    Schlaeppi, M.
    Moch, H.
    Schraml, P. H.
    Mjhic-Probst, D.
    Mamot, C.
    Schoenewolf, N.
    Dummer, R.
    ANNALS OF ONCOLOGY, 2012, 23 (02) : 531 - 536
  • [47] A Phase II Trial of Nab-Paclitaxel (ABI-007) and Carboplatin in Patients With Unresectable Stage IV Melanoma A North Central Cancer Treatment Group Study, N057E
    Kottschade, Lisa A.
    Suman, Vera J.
    Amatruda, Thomas, III
    McWilliams, Robert R.
    Mattar, Bassam I.
    Nikcevich, Daniel A.
    Behrens, Robert
    Fitch, Tom R.
    Jaslowski, Anthony J.
    Markovic, Svetomir N.
    CANCER, 2011, 117 (08) : 1704 - 1710
  • [48] Subcutaneous interleukin-2 and interferon-α plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma:: a phase II study
    Schmidt, H
    Geertsen, PF
    Fode, K
    Rytter, C
    Bastholt, L
    von der Maase, H
    MELANOMA RESEARCH, 2000, 10 (01) : 66 - 77
  • [49] Randomized Phase 2/3 Trial of CpG Oligodeoxynucleotide PF-3512676 Alone or With Dacarbazine for Patients With Unresectable Stage III and IV Melanoma
    Weber, Jeffrey S.
    Zarour, Hassan
    Redman, Bruce
    Trefzer, Uwe
    O'Day, Steven
    van den Eertwegh, Alfons J. M.
    Marshall, Ernest
    Wagner, Stefan
    CANCER, 2009, 115 (17) : 3944 - 3954
  • [50] BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
    Fujimura, Taku
    Hidaka, Takanori
    Kambayashi, Yumi
    Aiba, Setsuya
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (02) : 143 - 148
12345